

**FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)**

Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting

Tommy Douglas Conference Center
10000 New Hampshire Avenue, Silver Spring, Maryland
May 10, 2018

DRAFT AGENDA

The committee will discuss the safety and efficacy of new drug application (NDA) 210645, for volanesorsen solution for subcutaneous injection, submitted by Akcea Therapeutics, Inc. The proposed indication is as an adjunct to diet for the treatment of patients with familial chylomicronemia syndrome.

8:00 a.m.	Call to Order and Introduction of Committee	Peter Wilson, MD Chairperson, EMDAC
8:05 a.m.	Conflict of Interest Statement	LaToya Bonner, PharmD Designated Federal Officer, EMDAC
8:10 a.m.	FDA Introductory Remarks	John Sharretts, MD Clinical Team Lead (acting) Division of Metabolism and Endocrinology Products (DMEP), Office of Drug Evaluation II (ODE-II) Office of New Drugs (OND), CDER, FDA
8:20 a.m.	APPLICANT PRESENTATIONS	Akcea Therapeutics, Inc.
	Introduction	Louis St.L. O’Dea, MB BCh BAO. CSPQ. FRCP(C) Chief Medical Officer, Akcea Therapeutics
	Unmet Need: Disease Background	Daniel J. Rader, MD Seymour Gray Professor of Molecular Medicine Perelman School of Medicine University of Pennsylvania
	Pancreatitis	Steve Freedman, MD, PhD Professor of Medicine, Harvard Medical School Chief, Division of Translational Research Director, The Pancreas Center Beth Israel Deaconess Medical Center
	Efficacy	Louis St.L. O’Dea, MB BCh BAO. CSPQ. FRCP(C)
	Safety	Walter Singleton, MD Former Chief Medical Officer, Ionis Pharmaceuticals
	Risk Management	Michael Stevenson, RPh, PhD Head of Medical Affairs, Akcea Therapeutics

**FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)**

Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting
May 10, 2018

DRAFT AGENDA (cont.)

APPLICANT PRESENTATIONS (CONT.)

	Clinical Perspective	Seth J. Baum, MD, FACC, FACPM, FAHA, FNLA, FASPC President, American Society of Preventive Cardiology Affiliate Clinical Professor of Medicine Schmidt College of Medicine
9:50 a.m.	Clarifying Questions to Applicant	
10:05 a.m.	BREAK	
10:20 a.m.	FDA PRESENTATIONS	
	Clinical Review Introduction	Mary D. Roberts, MD Clinical Reviewer DMEP, ODE-II, OND, CDER, FDA
	Statistical Review of Efficacy	Alexander Cambon, PhD Statistical Reviewer Division of Biometrics II, Office of Biostatistics Office of Translational Sciences (OTS), CDER, FDA
	Clinical Review	Mary D. Roberts, MD
	Clinical Pharmacology Review	Yunzhao Ren, MD, PhD Clinical Pharmacology Reviewer Division of Clinical Pharmacology II Office of Clinical Pharmacology (OCP) OTS, CDER, FDA
	Risk Evaluation and Mitigation Strategy (REMS) Considerations	Ingrid N. Chapman, PharmD, BCPS Risk Management Analyst Division of Risk Management (DRISK) Office of Medication Error and Risk Management (OMEPRM) Office of Surveillance and Epidemiology (OSE) CDER, FDA
	Benefit/Risk Summary	Mary D. Roberts, MD
11:50 p.m.	Clarifying Questions to FDA	
12:05 p.m.	LUNCH	

**FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)**

Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting
May 10, 2018

DRAFT AGENDA (cont.)

- 1:05 p.m. **OPEN PUBLIC HEARING**
- 2:05 p.m. Questions to the Committee/Committee Discussion
- 3:45 p.m. **BREAK**
- 4:00 p.m. Questions to the Committee/Committee Discussion
- 5:00 p.m. **ADJOURNMENT**